Immuron completes manufacturing trial supplies of IMM-529
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Microbiome pharmaceutical group, Immuron (ASX:IMC) has successfully completed manufacturing trial supplies of its clinical drug product candidate IMM-529, a first in class oral immunotherapeutic targeting the prevention of Clostridium difficile infection (CDI) recurrence.
The drug was manufactured by the CSIRO Separations Science team and Pharmaceutical Packaging Professionals, partly funded by a grant of $50,000 from the Food Innovation Australia Ltd (FIAL) Enterprise Solutions Centre Program.
Commenting on this development, IMC’s Chief Executive, Thomas Liquard said, “IMM-529 is the second therapeutic drug candidate the company is progressing towards clinical trials, and this demonstrates that Immuron’s platform has the potential to develop multiple therapeutics which may result in several revenue opportunities for the company in the future.”
The market responded positively to the news with the company’s shares rallying 7.5% to an intraday high of 57.5 cents.
Although, it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
Discussing upcoming milestones, management said that human safety and efficacy studies of IMM-529 were expected to start by the end of the second quarter of 2017 and would be building on the positive pre-clinical results reported from a series of proof of concept efficacy studies completed by the Monash University in Melbourne. The outcomes of these results should be available in mid-2018.
IMM-529 is a biological product which is intended to prevent and treat CDI without destroying the microbiome, as is the case with antibiotic treatments, thus allowing the microbiome to return to a healthy state. The antibodies survive transit through the stomach and remain functional in the large intestine.
The planned Phase I/II clinical trials of IMM-529 will evaluate the safety and efficacy of the immunotherapy in combination with existing standards of care in 60 patients with acute and chronic CDI, a major medical problem causing an estimated annual economic cost of more than US$10 billion globally.
The condition is especially acute in hospitals and in long-term in patient care facilities with an estimated 29,000 patients dying each year in the US alone from the gut disease.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
